Neumora Therapeutics (NMRA) Other financing activities (2022 - 2025)

Neumora Therapeutics' Other financing activities history runs 4 years deep, the most recent figure standing at $216000.0 for Q4 2025.

• In Q4 2025, Other financing activities fell 82.4% year-over-year to $216000.0; the TTM figure through Dec 2025 stood at $275000.0 (down 96.32% YoY), while the FY2025 annual figure was $275000.0, down 96.32% from the prior year.
• Other financing activities for Q4 2025 stood at $216000.0, up from $59000.0 in the prior quarter.
• The five-year high for Other financing activities was $230.0 million in Q4 2023, with the low at $42000.0 in Q4 2022.
• The 4-year median for Other financing activities is $1.2 million (2024), against an average of $21.9 million.
• The sharpest annual moves came in 2023 and 2024: Other financing activities surged 547633.33% in 2023, then slumped 99.47% in 2024.
• Neumora Therapeutics' Other financing activities stood at $42000.0 in 2022, then soared by 547633.33% to $230.0 million in 2023, then plunged by 99.47% to $1.2 million in 2024, then slumped by 82.4% to $216000.0 in 2025.
• Business Quant data shows NMRA's Other financing activities at $216000.0 in Q4 2025, $59000.0 in Q2 2025, and $1.2 million in Q4 2024.